Clinical Studies
At Verb Biotics, science is the foundation for everything we do. We invest in clinical research to demonstrate how our ingredients perform in real life: by pairing purposeful innovation with rigorous clinical validation, we create solutions backed by evidence and built to make a meaningful impact on microbiome health.
Our Clinical Trials, Defined
Preclinicals
Preclinical studies help us understand how an ingredient works before advancing to human research. By evaluating the mechanism of action, we build the scientific foundation needed to confidently move promising solutions forward for clinical evaluation.
Human Clinicals
Human clinical studies put our science to the test where it matters most: in people. We conduct rigorous, double-blind, placebo-controlled studies to evaluate the efficacy of our ingredients and generate meaningful evidence behind their health benefits.
Animal Clinicals
Our animal clinical studies take a decentralized, at-home approach, allowing pets to remain in their natural environments throughout the study. This minimizes disruption to their daily lives while helping us evaluate how our ingredients perform under real-world conditions.
Keystone Postbiotic Clinical Outcomes
Mechanistic characterisation of a novel oat-based postbiotic: microbiome modulation, barrier protection, and wound healing
Goal: Evaluate Keystone Postbiotic's ability to provide health benefits by modulating the immune system and gut microbiome
Key Takeaways:
Increased Bifidobacterium abundance by 6.48-fold in an in vitro human fecal fermentation model
Maintained epithelial barrier integrity and accelerated wound closure under inflammatory conditions
Demonstrated coordinated effects on microbiome composition, epithelial function, and inflammatory signaling
The effects of a postbiotic supplement on biomarkers of microbiome, gastrointestinal, cardiometabolic, and immunometabolic health
Goal: Investigate the effects of Keystone Postbiotic on microbiome composition and selected biomarkers in a 4-week randomized, double-blind, placebo-controlled trial in generally healthy adults
Key Takeaways:
Selectively enriched 33 beneficial species —including Bifidobacterium— without disrupting microbiome diversity
Demonstrated exploratory effects on biomarkers of stress; 68% of participants reported improved emotional well-being
Selectively shifted the microbial ecosystem by decreasing the abundance of 38 taxa associated with impaired gut health
LP815 GABA Probiotic Clinical Outcomes
Lactiplantibacillus plantarum LP815 decreases anxiety in people with mild to moderate anxiety: a direct-to-consumer, randomised, double-blind, placebo-controlled study
Goal: This study assessed the impact of Lactiplantibacillus plantarum (LP815) on stress in adults with self-reported mild to moderate anxiety-related stress.
Key Takeaways:
68% of participants receiving LP815 improved by at least one GAD-7 severity category after 6 weeks
Significantly reduced self-reported feelings of irritability on the GAD-7 compared with placebo (P = 0.04)
LP815 significantly reduced GAD-7 scores by Week 4, with benefits maintained through Week 6
Lactiplantibacillus plantarum LP815 improves sleep and increases urinary GABA in a randomized, double-blind, placebo-controlled study of sleep disturbance
Goal: This study evaluated whether Lactiplantibacillus plantarum LP815 could improve sleep quality and elevate GABA levels in adults with self-reported sleep disturbances.
Key Takeaways:
77% of participants on LP815 achieved a clinically meaningful (≥4-point) improvement in sleep (ISI) scores
Night sweats trended down, with women exhibiting a steeper downward slope compared to men
LP815 significantly increased urinary GABA within the first week of supplementation
Efficacy of a Novel Lactiplantibacillus plantarum Strain (LP815) in Reducing Canine Aggression and Anxiety: A Randomized Placebo-Controlled Trial with Qualitative and Quantitative Assessment
Goal: This clinical trial evaluated the effects of Lactiplantibacillus plantarum LP815 on canine behavioral concerns, focusing on psychological distress, aggression, and sleep patterns in canines with human-reported behavioral issues.
Key Takeaways:
LP815 showed significant improvements in canine psychological distress after just 4 weeks (p = 0.0005)
Reduced aggression with a 0.48-point improvement on the validated C-BARQ scale (p = 0.0047)
Promoted calmer behavior with more consistent sleep and faster settling after owner departure, without signs of sedation
Sign up for our newsletter to be the first to know about future clinical publications.
Our solutions
Learn how our function-first bioactives deliver specific mechanisms of action for targeted health outcomes.
Let's talk
Find out how our biotics can be added into your food, beverage or dietary supplements to restore microbiome health for every body.